|
시장보고서
상품코드
1983185
항혈소판제 시장 : 약제 클래스별, 투여 경로별, 용도별, 지역별Antiplatelet Drugs Market, By Drug Class, By Mode of Administration, By Application, By Geography |
||||||
항혈소판제 시장은 2026년에 29억 700만 달러로 추정되고 있으며, 2033년까지 49억 2,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 7.83%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 29억 700만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2032년) | 7.83% | 예측 금액(2033년) | 49억 2,000만 달러 |
항혈소판제는 심근경색 병력이 있는 환자에게 처방되며, 심근경색 재발을 억제하는 데 도움이 됩니다. 항혈소판제에는 아스피린, 클로피도그렐, 프라수그렐, 티카그렐롤 등이 있습니다. 아스피린은 과민반응이 없는 한 급성관상동맥증후군(ACS)의 모든 환자에게 권장됩니다. 클로피도그렐, 프라수그렐, 티카그렐롤 등의 경구용 항혈소판제 중 하나와 병용 처방됩니다. 플러그렐은 ACS 환자나 경피적 관상동맥중재술(PCI)을 받는 환자에게 처방됩니다. 클로피도그렐과 티카그렐롤은 급성관상동맥증후군(ACS) 성인 환자 및 관상동맥우회술(CABG) 또는 관상동맥중재술(PCI) 치료를 받는 환자에서 죽상동맥혈전증 예방에 도움이 될 수 있습니다.
시장 역학
비만, 당뇨병, 심혈관 질환(CVD)과 같은 만성질환의 발생률 증가는 심장마비 위험을 증가시켜 항혈소판제에 대한 수요를 증가시키고 있습니다. 예를 들어 미국당뇨병협회에 따르면 2019년 미국 시민 3,730만 명, 즉 인구의 11.3%가 당뇨병을 앓고 있습니다. 이 3,730만 명의 성인 중 약 1,900만 명의 미국 시민이 제 1형 당뇨병을 앓고 있으며, 이 중 약 24만 4,000명의 소아 및 청소년이 포함되어 있습니다. 당뇨병을 앓고 있는 성인 3,730만 명 중 2,870만 명은 진단을 받았고, 850만 명은 미진단 상태였습니다. 2019년, 18세 이상 미국 시민권자 9,600만 명이 당뇨병 전단계에 해당합니다. 매년 140만 명의 미국 시민이 당뇨병 진단을 받고 있습니다. 미국 질병예방통제센터(CDC)의 보고에 따르면 2017-2018년까지 심장병으로 인한 미국내 연간 비용은 약 2,290억 달러에 달했습니다. 여기에는 의료 서비스 및 의약품 비용, 그리고 사망으로 인한 생산성 손실이 포함됩니다. 미국 질병예방통제센터(CDC)에 따르면 2019년 20세 이상 성인 중 약 2,010만 명이 관상동맥질환을 앓고 있다고 합니다.
이 보고서의 주요 특징
- 세계의 항혈소판제 시장을 상세하게 분석했으며, 2021년을 기준 연도로 하여 예측 기간(2022-2030년) 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트을 제공합니다.
- 세계 항혈소판제 시장의 주요 기업 개요을 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 작성되었습니다.
- 이 보고서의 인사이트을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- "세계 항혈소판제 시장" 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 항혈소판제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 항혈소판제 시장 : 약제 클래스별(2026-2033년)
제5장 세계의 항혈소판제 시장 : 투여 경로별(2026-2033년)
제6장 세계의 항혈소판제 시장 : 용도별(2026-2033년)
제7장 세계의 항혈소판제 시장 : 지역별(2026-2033년)
제8장 경쟁 구도
제9장 섹션
KSA 26.04.20Antiplatelet Drugs Market is estimated to be valued at USD 2,907 Mn in 2026 and is expected to reach USD 4,920 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.83% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,907 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.83% | 2033 Value Projection: | USD 4,920 Mn |
Antiplatelet drugs are prescribed to individuals with a history of heart attacks and these drugs aid in reducing reoccurrence of heart attacks. Some of the antiplatelet medications include, aspirin, clopidogrel, prasugrel, and ticagrelor. Aspirin is recommended for all patients with Acute Coronary Syndrome (ACS), in the absence of hypersensitivity. It is prescribed along with one of the oral antiplatelet agents including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed for patients suffering from ACS and for those undergoing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor aid in preventing atherothrombotic events in adult patients with ACS, and those who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.
Market Dynamics
Increasing incidence of chronic diseases such as obesity, diabetes, and cardiovascular diseases (CVDs) is increasing the risk of heart attacks, which in turn is propelling demand for antiplatelet drugs. For instance, according to American Diabetes Association, in 2019, 37.3 million U.S. citizens or 11.3% of the population, had diabetes. Of the 37.3 million adults, nearly 1.9 million U.S. citizens had type 1 diabetes, including about 244,000 children and adolescents. Of the 37.3 million adults with diabetes, 28.7 million were diagnosed, and 8.5 million were undiagnosed. In 2019, 96 million U.S. citizens age 18 and older had prediabetes. 1.4 million U.S. citizens are diagnosed with diabetes every year. According to report by Centers for Disease Control and Prevention, heart disease cost the U.S. about US$229 billion each year from 2017 to 2018. This included the cost of health care services, medicines, and lost productivity due to death. In the U.S. according to the Center for disease control, about 20.1 million adults age 20 and older had Coronary Artery Disease in the year 2019.
Key features of the study
- This report provides an in-depth analysis of the global antiplatelet drugs market , and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global antiplatelet drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global antiplatelet drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiplatelet drugs market
Market Segmentation
- Drug Class Insights (Revenue, USD Mn, 2026 - 2033)
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- Mode of Administration Insights (Revenue, USD Mn, 2026 - 2033)
- Oral
- Intravenous
- Application Insights (Revenue, USD Mn, 2026 - 2033)
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
- Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Otsuka Pharmaceutical Company, Ltd.
- Sanofi
- The Medicines Company
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Mode of Administration
- Market Snapshot, By Application
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- Epidemiology Analysis
- PORTER'S Five Forces
4. Global Antiplatelet Drugs Market, By Drug Class, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Irreversible Cyclooxygenase (COX) Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Glycoprotein IIB/IIIA Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adenosine Reuptake Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Antiplatelet Drugs Market, By Mode of Administration, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Intravenous
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Antiplatelet Drugs Market, By Application, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Angioplasty
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Arterial Thrombosis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Myocardial Infarction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Percutaneous Coronary Interventions
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Antiplatelet Drugs Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- AstraZeneca Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Daiichi Sankyo, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Otsuka Pharmaceutical Company, Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- The Medicines Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca Plc
9. Section
- References
- Research Methodology
- About Us and Sales Contact
